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Abstract – Shock is accompanied by generalised splanchnic hypoperfusion, and splanchnic organs
like the pancreas can be damaged, as shown in animal experimental models and in humans, by the
presence of high plasma concentrations of trypsin and other pancreatic enzymes. In order to design
a radioimmunoassay technique (RIA) for the measurement of equine trypsin-like immunoreactivity
(TLI) in biological fluids, trypsin was purified (with purity 96 %) from the equine pancreas by
extraction in an acid medium, ammonium sulfate precipitations, gel filtration chromatography and,
after activation of trypsinogen into trypsin, affinity chromatography. Gel polyacrylamide
electrophoresis showed a monomeric enzyme with a molecular weight of 27 kDa. The purified
equine trypsin served for the immunisation of rabbits in order to obtain a specific antiserum, and the
labelled antigen was prepared by iodination of equine trypsin with 125I. The RIA was based on the
binding of the antigen to the antibody followed by the separation of the antigen-antibody complex
by immunoprecipitation in the presence of sheep anti-rabbit gammaglobulins and the assay of the
radioactivity in the precipitate. The RIA showed good sensitivity, specificity, precision, accuracy
and reproducibility. The reference mean value of TLI in the plasma of healthy horses (n = 20) was
30.01 ± 6.84 ng/mL (upper confidence limit 50.52 ng/mL; p < 0.01). Three horses with non
strangulating intestinal obstruction without shock showed TLI values within normal limits whereas
5 of 7 horses with strangulation obstruction showed TLI levels above the upper confidence limit.
Further studies using the RIA and the enzymatic assay should be performed in order to confirm the
role of the pancreas in equine intestinal obstruction.
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1. INTRODUCTION 
Hypovolaemic and endotoxic shock fol-
lowing intestinal obstruction or severe sep-
sis may lead to generalised hypoperfusion
to which several organs (the central nerv-
ous system, lungs, heart, kidneys) are very
susceptible [28, 31, 39]. Hypoperfusion
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induces a systemic reaction with leukocyte
activation and a generalised inflammation
that finally leads to multiple organ failure
[3]. The organs of the splanchnic area are
also very susceptible to hypoperfusion,
although often clinically silent. Several
experimental studies have shown the par-
ticular susceptibility of the pancreas to
hypoperfusion with a decrease of capillary
blood flow, an increase of pancreatic
proenzymes and enzyme-complexes in the
general circulation and histo-pathological
alterations of the pancreas [12–15, 17, 23].
Similar findings have been made for
humans with severe trauma and hypovol-
aemic or septic shock [6, 22, 35, 47, 50].
Splanchnic hypoperfusion and systemic
inflammatory reaction contribute to pan-
creatic damage, with leukocyte accumula-
tion in the pancreatic capillaries and anoxia
of highly active metabolic rate cells of the
exocrine pancreas. Recently, digestive
enzymes were found to induce the forma-
tion of small molecular weight cell activa-
tors that may play an important role in the
development of microcirculatory dysfunc-
tion and multiple organ failure [32]. 
In horses, strangulating intestinal
obstruction often leads to the development
of endotoxic shock [34, 41]. Due to the
alteration of the intestinal permeability,
endotoxins enter the general circulation
[33], but the entry of digestive enzymes,
recognised as normal (in humans) to some
extent [8, 26] can also be increased. The
implication of the pancreas or pancreatic
enzymes in acute abdominal disease in the
horse has not, to date, been well docu-
mented. In a previous study, we have
shown the presence of high plasma
concentrations of active trypsin (probably
bound to 2-macroglobulin) in horses suf-
fering from strangulating intestinal
obstruction and endotoxic shock [19].
However, on the basis of current knowl-
edge concerning complex forms of human
and bovine trypsin, we can conclude that
the measurement of active trypsin does not
account for all the forms of trypsin that
may be present in the general circulation of
horses. In biological fluids, trypsin exists
under several forms, as an inactive precur-
sor (trypsinogen) and complex forms with
2-macroglobulin (2-M) and 1-protein-
ase inhibitor (1-PI) [9, 29, 36, 45]. In
physiological conditions, the presence of
free trypsin seems nearly impossible
because of large amounts of plasmatic
inhibitors [37]. The enzymatic assay of
trypsin only measures free trypsin and
trypsin bound to 2-M because this binding
does not inhibit the activity of the enzyme
but hinders its access for large molecular
weight substrates [38, 42]. The specificity
of trypsin RIA depends on the antigenic
properties of the enzyme but not on its
enzymatic activity [45]. The immunologi-
cal assay, based on the recognition by spe-
cific antibodies, thus permits the measure-
ment of trypsin-like immunoreactivity
(TLI). TLI is composed of trypsinogen,
free trypsin, trypsin bound to 1-PI, bound
to inter-1-trypsin inhibitor and even to
low molecular weight inhibitors such as
aprotinin or pancreatic secretory inhibitor
[15, 16, 24, 45]. Trypsin bound to 2-M is
buried in a pocket of this large molecule,
and is thus not recognised by the antibod-
ies because of steric inhibition [1, 5]. The
immunological method is thus comple-
mentary to the enzymatic assay and the
application of the two methods may deter-
mine the entire quantities of trypsin in bio-
logical fluids. An immunological assay of
equine trypsin has not yet been described,
and we only found one abstract concerning
its purification [21]. 
The aim of this study was to describe
the purification of equine trypsin and the
development of a radio-immunoassay
technique (RIA) for equine TLI. The puri-
fication was based on the method applied
for human trypsin [4, 30, 46] and the RIA
on the methods previously published relat-
ing to human trypsin [16, 30, 45]. The RIA
was applied to equine plasma for the deter-
mination of plasma values in healthy
horses in order to establish a reference
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range. Preliminary results in acute intesti-
nal obstruction are also mentioned.
2. MATERIALS AND METHODS
2.1. Reagents
The reagents used for the purification
and the development of the radioimmu-
noassay technique (RIA) were from Merck-
VWR International or Sigma-Aldrich,
Belgium (analytical grade), except where
otherwise indicated. Bovine albumin used
for the preparation of buffers was of RIA
quality (Sigma). Polyethylene glycol 6000
was from Fluka. Radioactive iodine (125I)
was from ICN laboratories (Na125I, carrier-
free, alkaline solution). The Sephadex gels,
ACA 44 and activated 4B Sepharose, and
the electrophoresis polyacrylamide gels
(SDS-PAGE) were obtained from Pharma-
cia (Amersham-Bioscience). Normal rabbit
serum and the sheep antiserum against
rabbit gammaglobulins were delivered by
the Laboratory of Hormonology (Centre
d’Économie Rurale, Marloie, Belgium).
Animal housing and immunisations were
performed at the Laboratory of Hormonol-
ogy (Centre d’Économie Rurale, Marloie,
Belgium). 
2.2. Protein measurement
The protein measurement was based on
the registration of absorbance at 280 nm dur-
ing the chromatographic steps of trypsin
purification. Protein concentration was
achieved by the spectrophotometric method
of Folin Ciocalteu for the dialysed and
concentrated extracts following purification.
2.3. Measurement of trypsin activity 
During the purification, the presence of
trypsin in the chromatographic fractions
was determined by the measurement of
its enzymatic activity using a low molecular
weight chromogenic substrate [either
D-L-benzoyl-arginine-p-nitranilide (BAPNA)
or carbobenzoxyl-valyl-glycyl-arginine
paranitranilide]. This technique is based on
the proteolytic cleavage by trypsin of the
chemical bond between arginine and para-
nitroanilide, releasing para-nitroaniline,
whose absorbance was monitored at
405 nm as previously described (kinetic
measurement, 15 min at 25 °C, spectropho-
tometer Perkin Elmer lambda 5 or on micro-
plates with the Multiscan Ascent reader
Thermolab Systems) [19, 27, 44]. BAPNA
was used (after trypsinogen activation) for
the gel filtration chromatography fractions
and carbobenzoxyl-valyl-glycyl-arginine
paranitranilide (more sensitive) for the
affinity chromatography fractions. In our
working conditions, we did not observe
interference with other pancreatic enzymes
like chymotrypsin, elastase, kallikrein, col-
lagenase, lipase, amylase and carbox-
ypeptidase [19]. 
2.4. Purification of equine trypsin
2.4.1. Tissue extraction, (NH4)2SO4 
precipitation and dialysis
We followed the method previously
described for the purification of human
trypsin [4, 46]. All the extraction steps were
conducted at +4 °C. The pancreas, from
horses euthanised for severe limb affections
and stored frozen (–70 °C), was extracted
(three times) in H2SO4 0.25 N, 0.1% Tween
20 (pH 2.5). The extract was centrifuged
for 30 min, firstly at 1 500 g, and secondly
at 20 000 g. The supernatant was treated
with ammonium sulfate (NH4)2SO4 firstly
at 20% saturation and secondly at 80% sat-
uration. The final precipitate (obtained after
centrifugation at 10 000 g, 30 min) was dia-
lysed in HCl 10–3 M and concentrated.
2.4.2. Chromatographic steps
and electrophoresis
The proteins (dissolved in the elution
buffer) were loaded on a gel filtration

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column (Sephadex G75) and eluted with
10–3 M HCl, 0.02 M CaCl2, 0.2 M NaCl,
pH 3.0. The trypsinogen-rich fractions
were identified by trypsin activity meas-
urement (BAPNA substrate) on a 100 µL
aliquot volume of each fraction (after
trypsinogen activation by 1% enteroki-
nase) pooled, dialysed and concentrated.
Trypsinogen in the protein pool was then
activated by 1% porcine enterokinase
(0.01 M Tris-HCl buffer, pH 7.8, 20 mM
CaCl2, 0.05 M NaCl; +4 °C, 6 h) [10]. The
last step was affinity chromatography on
4B Sepharose linked to aprotinin [30]. The
affinity column was successively eluted
with 0.1 M Tris-HCl buffer, NaCl 0.5 M,
pH 8.0 (elimination of unbound proteins),
0.1 M Na-acetate buffer, NaCl 0.5 M,
pH 4.5 (elimination of elastase and anionic
trypsin) and 0.1 M Tris-glycine buffer,
CaCl2 0.05 M, pH 2.5 to detach trypsin.
The trypsin-rich fractions, identified by
trypsin activity measurement (carboben-
zoxyl-valyl-glycyl-arginine paranitranilide
substrate) on a 50 µL aliquot volume of
each fraction, and adjusted to pH 4.0 with
0.05 M acetate buffer, were pooled, dia-
lysed against acetate buffer and concen-
trated. The protein concentration was
measured and the purity was estimated by
acrylamide gel electrophoresis in the pres-
ence of sodium dodecyl sulphate (SDS-
PAGE 8-18) in non reducing/denaturating
[40] and in reducing/denaturating condi-
tions [51]. Equine trypsin for immunisation
and RIA was kept in a solid form (aliquot
fractions) at –70 °C. Degradation studies
were performed on trypsin solutions and
on aliquot fractions of solid trypsin kept at




Two rabbits were immunised by an
intradermic injection of 100 µg of equine
trypsin (emulsified in 0.05 M phosphate
buffer, 0.15 M NaCl, pH 7.4 supplemented
with complete Freund adjuvant) followed
by booster injections of 50 µg every
15 days [7, 48]. Blood samples were col-
lected 12 days after each booster injection.
The serum was then analysed for its immu-
nological reaction with equine trypsin by
radial immunodiffusion and by binding
to equine 125I-labelled trypsin (labelled
antigen). The titer of the final blood sam-
pling (rabbit exsanguination under anaes-
thesia) was defined as the highest antise-
rum dilution still binding 30% of the
labelled antigen [7].
2.5.2. 125I labelling
Equine trypsin (5 µg in 5 µL of 0.5 M
phosphate buffer at pH 7.4) was achieved
by chemical binding of 125I (1 mCi Na125I,
carrier-free, in an alkaline solution,) in the
presence of 20 µg of chloramine T [18, 30].
The reaction was stopped after 30 s by the
addition of 20 µg of sodium metabisulfite
(Na2S2O5) and dilution with 0.05 M phos-
phate buffer, pH 7.4. Unbound 125I was
eliminated by gel filtration chromatogra-
phy on Sephadex G-25 eluted with 0.05 M
phosphate buffer, 0.05% NaN3 and 0.5%
bovine serum albumin. The fractions
(1 mL) with the highest radioactivity
( counter RIASTAR-Canberra-Packard)
were pooled and further purified by gel fil-
tration on ACA 44 (elution with the same
phosphate buffer) to eliminate polymerised
or degraded forms of the enzyme. The frac-
tions with the highest radioactivity were
pooled, kept at –70 °C and used within
15 to 20 days. Before RIA incubation,
the labelled antigen was diluted to
± 40 000 cpm/100 µL (tracer). 
2.5.3. RIA procedure 
The RIA method was a double-antibody
technique (immunoprecipitation of the
antigen-antibody complexes in the pres-
ence of sheep anti-rabbit-gammaglobulins)
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with competition between the tracer and
the TLI for a fixed amount of antibodies
[20]. All the RIA reagents were diluted in
the “incubation buffer”: 0.05 M phosphate
buffer, 0.05% NaN3 and 0.5% bovine
serum albumin. The following solutions
were left to incubate (various incubation
times and temperatures were tested):
(a) 100 µL of the tracer, (b) 100 µL of the
successive dilutions of equine trypsin
(from 1.25 to 250 ng/mL) or 100 µL of the
plasma to be tested, (c) 100 µL of antise-
rum (1/6 000 dilution). At the end of the
incubation, 100 µL 0.1% normal rabbit
serum and 1 mL of the precipitation solu-
tion (incubation buffer added with 60 g/L
polyethylene glycol 6000, 200 mg/L of
microcrystalline cellulose, 5 mL/L of
Tween 20 and 0.5% sheep anti-rabbit gam-
maglobulin serum) were added and incu-
bation was continued for 20 min at room
temperature. Free and antibody-bound
antigens were separated by centrifugation
(2000 g, 20 min), and the precipitates were
counted. The results are expressed as the
ratio (B/B0, expressed in %) between the
amount of the tracer bound to the antibod-
ies in the presence (B) and in the absence
(B0) of equine trypsin. The B/B0 values
calculated for the unknown samples are
reported on a standard curve to obtain the
TLI value in ng/mL [7].
The optimal conditions of RIA were
achieved when the duration, the tempera-
ture of incubation and the final dilution of
the antiserum permitted a 40% value for
B0, with a non-specific binding not
exceeding 5%. 
2.6. Characteristics of the RIA
and application to equine plasma 
samples
2.6.1. Specificity, sensitivity, precision, 
accuracy, and reproducibility
The cross-reactivity of the antiserum
was tested with equine albumin and the
total protein contents of blood cells (iso-
lated leucocytes or erythrocytes used after
homogenisation). The sensitivity was
defined as the minimum amount of unla-
belled trypsin that caused a reduction in the
percent of the labelled antigen bound to the
antibody, greater than twice the standard
deviation of 10 determinations of B0. The
precision was estimated by the coefficient
of variation calculated for 10 determina-
tions of each standard trypsin concentra-
tion. The accuracy was estimated by the
recovery of known amounts of trypsin
added to equine plasma samples. The
reproducibility was measured by the coef-
ficient of variation calculated for at least
five determinations of the same sample
within or between assays [7].
2.6.2. Normal and pathological values
We established a reference range for
TLI values in the plasma and serum of
healthy horses (n = 20), and applied the
RIA to the plasma of horses suffering from
acute intestinal obstruction (n = 10). In
these horses, TLI was assayed on admis-
sion (P1), during the surgery (P2) and the
intensive care period about 24 hours after
the end of surgery (P3). Another plasma
sample (P4) was obtained when severe
complications occurred or when the horse
completely recovered a normal intestinal
function (3–4 days after the surgery)
except for the horses No. 9 and 10, which
died early after the surgery. 
3. RESULTS
3.1. Isolation of equine trypsin
3.1.1. Extraction and chromatography 
After acid extraction of the pancreas, we
obtained a precipitate containing 7 284 mg
of proteins. Ammonium sulphate precipi-
tations eliminated ±80% of these proteins.
Gel filtration chromatography on Sepha-
dex G75 eliminated the remaining proteins
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with molecular weight >80 kDa, and
trypsinogen was detected in the second
peak (Fig. 1). The pool of trypsinogen-rich
fractions (fractions 23 to 34) was activated
with enterokinase to release trypsin, and
used for affinity chromatography. This
second chromatography step eliminated
the remaining pancreatic proteins (eluted
in the first and second peaks). The trypsin
rich fractions (fractions 28 to 32) were
detected in the last peak (Fig. 2). From
122 g of equine pancreas, 18 mg of
lyophilised proteins with a trypsin enzy-
matic activity >90% were obtained at the
end of the purification procedure (extrac-
tion rate of 0.25%).
Figure 1. Gel filtration chromatography (Sephadex G-75) of the equine pancreas extract. Left
ordinate: _____ absorbance of the proteins at 280 nm; right ordinate: ••••• trypsin enzymatic activity
(measured on a 100 µL aliquot of each eluted fraction after trypsinogen activation with
enterokinase).  pool of trypsinogen-rich fractions.
Figure 2. Last step of equine trypsin purification: affinity chromatography on sepharose-aprotinin.
Left ordinate: _____ absorbance of the proteins at 280 nm; ••••• right ordinate: trypsin enzymatic
activity (measured on a 50 µL aliquot of each eluted fraction).  pool of trypsin-rich fractions.
Arrows indicate the changes of the elution buffer.
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3.1.2. SDS-PAGE analysis 
SDS-PAGE performed on the pool of
trypsinogen-rich fractions obtained after
gel filtration chromatography, showed two
bands at ±27 and ±26 kDa, a large band at
±18 kDa and a lot of low molecular
weight bands (Fig. 3, part A). The 27 and
±26 kDa bands slowly developed a posi-
tive enzymatic response in the presence of
carbobenzoxyl-valyl-glycyl-arginine para-
nitranilide. In reducing and denaturating
conditions, no changes were observed in
the electrophoretic profile.
The final preparation showed 96%
purity as estimated by gel electrophoresis
(densitometry on the stained gel) (Fig. 3,
part B). The SDS-polyacrylamide gel elec-
trophoresis in non reducing/denaturating
conditions showed one band with a molec-
ular weight of ±27 kDa. Enzymatic activity
was detected on this 27 kDa band. The
electrophoresis of the enzyme after reduc-
ing/denaturating treatment did not show
any additional band suggesting that the
enzyme was monomeric. 
3.1.3. Degradation analysis
When trypsin was kept in solution at
–20 °C for three months, new electro-
phoretic bands (<10 kDa and mainly
around 3 kDa) were observed (without
enzymatic activity), attributed to small
trypsin degradation fragments. Lyophilised
trypsin kept in the same conditions did not
show degradation bands. At –70 °C after
6 months, no degradation was observed for
equine trypsin powder but was present for
trypsin solutions: electrophoresis showed
two major fragments (± 15 and 12 kDa)
that still retained enzymatic activity. 
 
Figure 3. Analysis of purified equine trypsin by SDS polyacrylamide (8-18) gel electrophoresis.
Part A: Electrophoresis of equine trypsinogen obtained after gel filtration chromatography. Lane 1:
bovine albumin; lane 2: bovine trypsin/trypsinogen; lane 3: equine trypsinogen after gel filtration
chromatography: bands a are trypsinogen and band b represents proteins with molecular weight
around 18 kDa (no enzymatic activity). 
Part B: Electrophoresis of equine trypsin obtained after affinity chromatography. Lane 5: molecular
mass markers (d: bovine albumin, 67 kDa; c: ovalbumin, 43 kDa; b: carbonic anhydrase, 30 kDa;
a: aprotinin, 12 kDa). Lanes 4 and 3: equine trypsin (40 µg and 20 µg) after affinity chromatography
(no reduction and no denaturation). Lane 2: same as lane 3 after reduction and denaturation).
Lane 1: bovine trypsin/trypsinogen (40 µg). Arrow indicates the migration direction (part A and B).
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3.1.4. Main characteristics of the final 
equine trypsin
The enzymatic activity (with carboben-
zoxyl-valyl-glycyl-arginine paranitrani-
lide used as the substrate) was Ca2+-
dependent with optimal concentrations
around 20 mM and was maximal at pH 8.0.
It was also inhibited by aprotinin and the
soybean trypsin inhibitor (molecular ratio
inhibitor/trypsin 2/1), azide and benzami-
dine (molecular ratio inhibitor/trypsin 500/1).
Equine trypsin activity on low molecular
weight substrates was reduced by albumin
(0.5%) and equine plasma. 
3.2. Labelling and immunisation
Lyophilised batches of equine trypsin,
without degradation, were used for rabbit
immunisation. From two rabbits, we
obtained two antisera that were used at an
initial dilution of 1/6 000 with a maximal
B0 value of 40% achieved after 4 h of incu-
bation, either at +4 °C or room temperature
(18–20 °C), remaining stable for 36 h of
incubation, with non-specific binding
between 2 and 4%. The chloramine T tech-
nique of labelling followed by gel filtration
chromatography yielded a labelled anti-
gen, uncontaminated by free iodine and
degraded trypsin forms. The tracer was
used at a dilution of 40 000 cpm/100 µL
and remained immunoreactive until
20 days after labelling.
3.3. RIA conditions
The RIA conditions were the following:
total activity adjusted to 40 000 cpm for
100 µL of labelled antigen solution, antise-
rum at a dilution of 1/6 000 with an incuba-
tion time of 16–18 h (overnight), repre-
senting the easiest laboratory conditions.
Figure 4 shows that the lower detection
limit of the RIA was 4 ng trypsin or TLI/mL
and that the upper limit was 200 ng/mL.
The reference curve was obtained at room
temperature and superimposed on the
curve obtained at +4 °C (Fig. 4). From
these results, we chose an overnight incu-
bation at +4 °C for easy working condi-
tions during our subsequent assays. The
coefficient of variation calculated from
10 determinations of each point of the ref-
erence curve was always lower than 4% for
equine trypsin concentrations ranging
from 10 to 150 ng/mL, indicating an excel-
lent reproducibility. The coefficient of var-
iation intra- and interassay (n = 10) for
Figure 4. Standard curves of RIA for equine TLI. Two incubation conditions were compared: 24 h
at +4 °C or 24 h at room temperature. The reference molecule was undegraded equine trypsin.
Arrow indicates the limit of sensibility of the RIA (4 ng/mL).
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unknown plasma samples never exceeded
6% (in the linear part of the curve). The
recovery of known amounts of equine
trypsin (from 10 to 100 ng/mL) added to
serum samples was ±90%, indicated a
high level of accuracy. There was no cross-
reaction with albumin or with the intracel-
lular content of equine leucocytes or eryth-
rocytes. 
3.4. Application to plasma samples
and establishment of a reference 
range 
The values measured in the plasma of
healthy horses (n = 20) are represented in
Figure 5, with a mean value of 30.01 ±
6.84 ng/mL. The mean value + 3 SD
(50.52 ng/mL) was chosen for the upper
confidence limit with a probability of error
of p < 0.01. In serum samples (n = 20, the
same horses as for the plasma measure-
ment), the normal value was 32.05 ± 6 ng/mL,
not statistically different from the plasma
values.
3.5. Preliminary results in acute 
intestinal obstruction
Three horses showed non-strangulating
lesions without post-operative complica-
tions. Their TLI values always remained
within the normal limits (horses No. 1, 2
and 3; Tab. I). Seven horses were pre-
sented with strangulating small or large
intestine obstruction. Five of them, three
on admission (horses No. 7, 9 and 10;
Tab. I), one after surgery (horse No. 6) and
one during the post-operative phase (horse
No. 4; Tab. I) did show an increase in the
TLI values above the normal physiological
values. In particular, two horses (No. 9 and
10) with severe intestinal lesions that did
not survive had very high levels in each
plasma sample (Tab. I).
In Figure 5 (parts B and C), we com-
pared the highest individual value meas-
ured for each horse with acute intestinal
obstruction to the individual values of the
reference horses (part A).
4. DISCUSSION 
4.1. Purification of equine trypsin
Apart from a short abstract [21], the
purification of equine trypsin has never
been described extensively, in contrast to
the enzyme in humans, bovines and many
other species. Therefore, we designed a
purification method for equine trypsin
based on our experience with human
trypsin and on previously reported meth-
ods of trypsin purification [4, 25, 46]. The
first purification steps were conducted in
an acid milieu thus permitting the limita-
tion of the autoactivation of trypsinogen
and avoidance of the addition of enzymatic
inhibitors during the purification. They
eliminated ±80% of the total protein
Figure 5. Individual values of plasma TLI (ng/
mL). A: in 20 healthy horses (REF), with mean
reference value (______) and upper limit of
normal (______). B: maximal value measured in
3 horses with non strangulating intestinal
obstruction (NSIO). C: maximal value
measured in 7 horses with strangulation
obstruction (SIO). ______ Upper limit of normal.
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content, and gel filtration chromatography
(G-75) removed 50% of the remaining pro-
teins with a molecular weight 80 kDa. At
this point, we isolated trypsinogen, but a
low trypsin activity could be detected
in the fractions corresponding to the last
part of the first protein peak eluted
from the gel filtration column, this being
attributed to the presence of unstable
trypsin complexes with pancreatic high
molecular weight inhibitors. From electro-
phoresis, we concluded that the pool of
trypsinogen-rich fractions contained quan-
tities of contaminating proteins of low
molecular weight, requiring a new purifi-
cation step. No explanation can be given
for the presence of two trypsinogen bands:
their slow kinetics of autoactivation indi-
cated the absence of trypsin and suggested
the existence of two forms of equine
trypsinogens, conditions similar to those
reported for human trypsinogen [4, 10].
This hypothesis has to be confirmed by
complementary studies.
Affinity chromatography yielded a pure
monomeric protein, positive for enzymatic
detection, and not contaminated by elastase
or chymotrypsin (their enzymatic activities
were not detectable using specific low
molecular weight substrates). 
Molecular weight was estimated around
27 kDa. There is little published data on
the equine trypsin: Harris and Hofmann
[21] isolated the equine trypsinogen with a
molecular weight of 25.6 kDa. Walsh [49]
(reporting complementary data obtained as
a personal communication from Hofmann)
attributed a total of 226 to 229 amino acids
(201 for human trypsinogen) to equine
trypsinogen, with a N-terminal sequence
of 8 amino acids, which is split to produce
active trypsin. By electrophoresis, we
found similar results, but molecular weight
Table I. Trypsin-like immunoreactivity (TLI) in horses with intestinal obstruction (n = 10).







3–4 days after 
surgery (P4)
1* Ileum impaction S 17 28 13 7
2* Large colon 
displacement
S 13 14 10 11
3* Large colon 
displacement
S 31 38 32 26
4** Ileal incarceration in 
epiploic foramen
S 19 50 19 96
5** Ileal incarceration in 
epiploic foramen
S 17 14 17 7
6** Large colon torsion S 29 71 22 19
7** Large colon torsion S 230 98 34 20
8** Jejunal incarceration 
in epiploic foramen
NS 31 20 7 10
9** Volvulus of the 
jejunum
NS 800 180 178 §
10** Large colon torsion NS 500 546 210 §
* Non strangulating obstruction; ** strangulation obstruction.
S: survivor; NS: non survivor. §: no value (death shortly after surgery).

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determinations by electrophoresis are not
very precise, and the exact molecular
weight of equine trypsin will only be
known after complete sequencing. 
In our working conditions, the yield of
extraction was low, mainly due to the
incomplete activation of trypsinogen by
enterokinase. The remaining trypsinogen
was detected after activation in the peak on
unbound proteins and eluted with the first
buffer (pH 8.0) on the affinity column. 
The global scheme of purification was
similar to that used for the human enzyme
[4, 30, 46], and was rapid, but had a low
efficiency due to the incomplete activation
of trypsinogen into trypsin by enteroki-
nase. This low activation could be attrib-
uted to the pH of the milieu (pH 7.8) and to
the time and temperature of activation (6 h
at +4 °C). This pH value was chosen
because it allowed an easy pH adjustment
necessary for the next step of purification
(pH 8.0). The time and the temperature
were chosen to limit the degradation of
trypsin during the activation. For the next
purification, activation will be performed
at pH 6.0 a value near the physiological
value for enterokinase activity. We did not
choose the autoactivation of trypsinogen at
pH 8.0 in the presence of Ca2+ because this
technique needed a longer reaction time at
room temperature, with an increased risk
of degradation. Moreover, we could not
exclude the possibility that, after the gel
filtration chromatography step, pancreatic
inhibitors remained in the pool of proteins
used for activation. These inhibitors would
block free trypsin already present in the
pool, slowing the autoactivation and
increasing the degradation. Finally, we had
doubts about the correct Ca2+ concentra-
tion to be used, since previous studies on
human and bovine trypsinogens demon-
strated major differences, and that exces-
sive concentrations of this ion were inhibi-
tors on human trypsinogen activation [4]. 
Equine trypsin reacted like human or
bovine trypsin with classical inhibitors of
serine proteases and was inhibited by
plasma [9, 10, 37]. Its inhibition by 2-M
or 1-PI remained unknown on account of
the need for purification of these equine
anti-proteases prior to testing. The role of
equine plasma can be attributed to trypsin
trapping by 2-M, slowing the enzymatic
activity on the substrate. Albumin has
never been described as an inhibitor, but as
a protector of trypsin [30]. Its “in vitro
effect” on equine trypsin can be attributed
to a “competitive” action of albumin slow-
ing the reaction of trypsin with the car-
bobenzoxyl-valyl-glycyl-arginine parani-
tranilide substrate. 
The equine enzyme seemed to be fragile
in solution, as shown by the presence of
small bands of degradation observed by
electrophoresis. The degradation remained
rapid, even when the enzyme was stored
frozen at –70 °C. But, the final preparation
of equine trypsin was lyophilised and kept
in this solid form at –70 °C. Trypsin solu-
tions were prepared for immediate use
(before labelling and before injection for
rabbit immunisation); it thus seemed
unlikely that they contained seriously
degraded forms.
4.2. Establishment of the RIA
We applied the classical 125I labelling
technique with chloramine T, as previ-
ously used for many proteins [18] and for
human trypsin [30] and obtained a labelled
antigen that was stable for 20 days in phos-
phate buffer supplemented with bovine
serum albumin. We obtained two antisera
that were used at a dilution of 1/6 000
(yielding 40% of binding of the labelled
antigen). The equilibrium of the antibody-
antigen reaction was reached after 4 h of
incubation at +4 °C or room temperature
and did not vary until 36 h of incubation.
Thus, the conditions of the assay, 16–18 h
of incubation at +4 °C, were chosen to
facilitate the work: overnight incubation
allowed an easy planning of the assays, and
+4 °C provided a fixed temperature inde-
pendent of laboratory temperature varia-
tions. 
328 S. Grulke et al.
The reference curve showed a good sen-
sitivity of the RIA with a detection thresh-
old of 4 ng/mL and a superior limit of
200 ng/mL, comparable to the reference
curves and the sensitivity limits (from 0.6
to 10 ng/mL) previously established for the
RIA in other species [2, 11, 16, 30, 43, 45,
52]. The intra- and interassay variation
coefficients were low, never exceeding 6%
for trypsin values in the linear part of the
reference curve, indicating that the RIA
was precise and reproducible. The assay
was specific because the antibodies did not
recognise albumin or the global content of
equine leukocytes or erythrocytes. There
was no cross-reaction with human or
bovine trypsin/trypsinogen. A high degree
of accuracy was achieved, since 90% of the
added amounts of trypsin were detected by
the assay. 
4.3. Estimation of normal
and pathological values
The mean value of TLI in the horse
(30.01 ± 6.84 ng/mL) was similar to the
mean value observed in humans (26–30 ±
12 ng/mL) [2, 6, 11, 16, 24, 30] and other
species [14, 43, 52]. The superior limit of
normal values was 50 ng/mL (correspond-
ing to the mean value + 3 SD, p < 0.01). In
the absence of previously described equine
TLI RIA, no comparison could be made,
nevertheless, the value was similar to the
human maximal physiological value of
70 ng/mL [25]. The sampling conditions
(immediate versus delayed centrifugation),
the use of serum or anticoagulated blood,
and the type of anticoagulant, did not influ-
ence the results of TLI in the horse. This
conformed to observations in humans but
should be examined on a larger number of
horses. Within the samples of horses suf-
fering from intestinal obstruction, only
those cases with strangulation obstruction
showed high TLI concentrations, this
increase being observed in horses suffering
from small as well as large intestine
obstruction. In a previous study [19], we
already demonstrated an increase in the
plasma active trypsin concentration in
horses suffering from intestinal obstruc-
tion and shock, and the assay of TLI we
report in this study was complementary to
the assay of trypsin activity. Further stud-
ies using the two assay methods should be
led in order to evaluate the degree of pan-
creatic implication in equine acute abdom-
inal disease. 
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